Rating Watching: BMO Capital Keeps $87.00 TP On Medtronic plc (NYSE:MDT), Keeps “Outperform” Rating

November 23, 2016 - By whatsonthorold

Rating Watching: BMO Capital Keeps $87.00 TP On Medtronic plc (NYSE:MDT), Keeps

Medtronic plc (NYSE:MDT) Rating

They currently have a $87.00 target price per share on Medtronic plc (NYSE:MDT). BMO Capital’s target would suggest a potential upside of 14.72% from the company’s last stock price. This was revealed to investors in a research note on Wednesday, 23 November.

Medtronic PLC (NYSE:MDT) Ratings Coverage

Out of 17 analysts covering Medtronic (NYSE:MDT), 13 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 76% are positive. $102 is the highest target while $82 is the lowest. The $90.43 average target is 19.24% above today’s ($75.84) stock price. Medtronic has been the topic of 23 analyst reports since August 10, 2015 according to StockzIntelligence Inc. Evercore upgraded the stock to “Buy” rating in Thursday, October 8 report. Deutsche Bank maintained the stock with “Buy” rating in Thursday, June 2 report. Credit Suisse reinitiated the shares of MDT in a report on Monday, August 10 with “Outperform” rating. UBS maintained the stock with “Buy” rating in Friday, August 26 report. BTIG Research downgraded Medtronic PLC (NYSE:MDT) on Wednesday, June 1 to “Neutral” rating. The stock of Medtronic PLC (NYSE:MDT) has “Hold” rating given on Friday, September 4 by Jefferies. Credit Suisse maintained it with “Outperform” rating and $85 target price in Monday, November 23 report. The firm has “Buy” rating by SunTrust given on Monday, April 25. As per Thursday, March 17, the company rating was initiated by Nomura. The stock has “Buy” rating given by Needham on Tuesday, June 7.

About 10.75 million shares traded hands or 76.81% up from the average. Medtronic PLC (NYSE:MDT) has declined 6.27% since April 21, 2016 and is downtrending. It has underperformed by 11.60% the S&P500.

Insitutional Activity: The institutional sentiment decreased to 0.73 in Q2 2016. Its down 0.07, from 0.8 in 2016Q1. The ratio worsened, as 60 funds sold all Medtronic PLC shares owned while 508 reduced positions. 93 funds bought stakes while 361 increased positions. They now own 1.03 billion shares or 1.89% more from 1.01 billion shares in 2016Q1.

Hilltop last reported 4,345 shares in the company. Westfield Capital Management Commerce Limited Partnership holds 0% or 2,978 shares in its portfolio. Highlander Llc has 11,256 shares for 0.89% of their US portfolio. Pacwest Fincl Mngmt, a Arizona-based fund reported 21,973 shares. Moreover, Cue Finance Group Incorporated has 0.32% invested in Medtronic PLC (NYSE:MDT) for 4,266 shares. Da Davidson has 0.1% invested in the company for 39,049 shares. Panagora Asset Mngmt has invested 0.14% of its portfolio in Medtronic PLC (NYSE:MDT). Blackrock Gru Limited holds 12.66M shares or 0.57% of its portfolio. Northstar Invest Ltd Com holds 89,119 shares or 1.78% of its portfolio. Moors & Cabot owns 44,456 shares or 0.68% of their US portfolio. Honeywell, a New Jersey-based fund reported 333,600 shares. Front Barnett Ltd Liability Company holds 1.9% of its portfolio in Medtronic PLC (NYSE:MDT) for 108,199 shares. Auxier Asset holds 2.76% of its portfolio in Medtronic PLC (NYSE:MDT) for 139,173 shares. Marco Llc accumulated 136,374 shares or 2.2% of the stock. Fort Washington Inv Advsrs Inc Oh holds 0.08% of its portfolio in Medtronic PLC (NYSE:MDT) for 48,924 shares.

Medtronic Public Limited Company is a medical technology and services company. The company has a market cap of $103.18 billion. The Firm develops, makes and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. It has a 29.47 P/E ratio. The Firm operates in four divisions: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

According to Zacks Investment Research, “Medtronic is the world’s leading medical technology company, pioneering device-based therapies that restore health, extend life and alleviate pain. Primary products include those for bradycardia pacing, tachyarrhythmia management, atrial fibrillation management, among others. Medtronic operates its business in one reportable segment, that of manufacturing and selling device-based medical therapies. The company does business in more than 120 countries. The company’s product lines include cardiac rhythm management, neurological and spinal, vascular and cardiac surgery.”

MDT Company Profile

Medtronic Public Limited Company (Medtronic), incorporated on June 12, 2014, is a medical technology, services and solutions company. The Firm operates in four divisions: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes cardiac rhythm and heart failure, coronary and structural heart, and aortic and peripheral vascular. The Company’s Minimally Invasive Therapies Group segment includes surgical solutions, and patient monitoring and recovery. The Company’s Restorative Therapies Group segment includes spine, neuromodulation, surgical technologies and neurovascular. The Company’s Diabetes Group segment includes intensive insulin management, non-intensive diabetes therapies, and diabetes services and solutions. The Company’s subsidiaries include Medtronic, Inc. and HeartWare International, Inc.

More recent Medtronic PLC (NYSE:MDT) news were published by: Reuters.com which released: “Medtronic sales disappoint, firm lowers forecast; shares fall” on November 22, 2016. Also Investorplace.com published the news titled: “Why Medtronic PLC (MDT), Dycom Industries, Inc. (DY) and Palo Alto Networks …” on November 22, 2016. Investorplace.com‘s news article titled: “Medtronic PLC (MDT) Stock Oozes Long-Term Strength” with publication date: November 02, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>